Program of Chemical Biology, Institute of Cell and Molecular Biology, Biomedical Centre, Uppsala University, SE-75123 Uppsala, Sweden.
Bioorg Med Chem Lett. 2013 May 1;23(9):2750-8. doi: 10.1016/j.bmcl.2013.02.054. Epub 2013 Feb 22.
Here we report identification of new lead compounds based on quinoline and indenoquinolines with variable side chains as antiprotozoal agents. Quinolines 32, 36 and 37 (Table 1) and indenoquinoline derivatives 14 and 23 (Table 2) inhibit the in vitro growth of the Trypanosoma cruzi, Trypanosoma brucei, Trypanosoma brucei rhodesiense subspecies and Leishmania infantum with IC50=0.25 μM. These five compounds have superior activity to that of the front-line drugs such as benznidazole, nifurtimox and comparable to amphotericin B. Thus these compounds constitute new 'leads' for further structure-activity studies as potential active antiprotozoal agents.
在这里,我们报告了以喹啉和茚并喹啉为基础的新型先导化合物的鉴定,这些化合物具有可变的侧链,可用作抗原生动物药物。喹啉 32、36 和 37(表 1)和茚并喹啉衍生物 14 和 23(表 2)抑制了体外生长的克氏锥虫、布氏锥虫、布氏锥虫罗得西亚亚种和婴儿利什曼原虫,IC50=0.25 μM。这五种化合物的活性优于一线药物,如苯并咪唑、硝呋替莫和两性霉素 B。因此,这些化合物构成了进一步结构活性研究的新“先导化合物”,作为有潜力的抗原生动物药物。